Feature

Model Medicines innovates by bringing together data science and biology to develop drugs

Closely-held Model Medicines is spearheading the use of AI to model chemistry and human biology, empowering drug discovery and creating novel, best-in-class therapeutics for diseases with high unmet medical needs at...

September 3, 2024

Feature

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

Entera Bio (NASDAQ:ENTX) is leveraging a disruptive technology platform called N-Tab to develop first-in-class, once-daily oral tablets of peptides and small therapeutic protein replacement therapies. The company...

August 20, 2024

Feature

Mauna Kea launches groundbreaking food-related IBS detection and treatment program

Mauna Kea Technologies (Euronext Growth:ALMKT), inventor of the world’s first and only real-time in vivo cellular imaging platform, Cellvizio, designed to deliver high-magnification visualization of cellular structures...

August 6, 2024

Feature

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

BerGenBio (OSE: BGBIO) is developing a pipeline of transformative drugs targeting AXL as a cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections.

July 16, 2024

NEWS

Just a few of the companies we’ve highlighted along the way

Giving healthcare companies and their stories the exposure they deserve.

Model Medicines innovates by bringing together data science and biology to develop drugs

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

Mauna Kea launches groundbreaking food-related IBS detection and treatment program

BerGenBio pioneering cutting-edge AXL therapies to fight aggressive diseases

NEWS

Cidara’s workforce restructuring enables focus on clinical development

Tenon prepares to launch new joint fixation device with 30% reduction in implant width

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

Therma Bright adds pharma veteran Douglas S. Sommerville to AB

Creyon Bio appoints venture capitalists Serge Messerlian and Shaquille Vayda to board

Vor Bio reports data validating shielded transplants and early evidence of patient benefit

Ocuphire doses first participants in Phase 3 presbyopia study

NIH awards TransCode with $2 million grant for lead therapeutic

Aurinia reports first participant dosed milestone for potential therapy in autoimmune diseases

Just a few of the companies we’ve highlighted along the way

General

More